IN165717B
(de)
*
|
1986-08-07 |
1989-12-23 |
Battelle Memorial Institute |
|
US5529932A
(en)
*
|
1988-01-28 |
1996-06-25 |
Pharmacia, S.P.A. |
Isolated DNA encoding a plant ribosome inactivating protein from the leaves of saponaria officinalis
|
IL106992A
(en)
*
|
1988-02-11 |
1994-06-24 |
Bristol Myers Squibb Co |
Noble hydrazonic history of anthracycline and methods for their preparation
|
DE4004573A1
(de)
*
|
1989-02-17 |
1990-08-23 |
Tanabe Seiyaku Co |
Neues versuchstier und seine herstellung
|
US5354844A
(en)
*
|
1989-03-16 |
1994-10-11 |
Boehringer Ingelheim International Gmbh |
Protein-polycation conjugates
|
US5191067A
(en)
*
|
1989-04-27 |
1993-03-02 |
The Salk Institute For Biological Studies |
Fibroblast growth factor conjugates
|
US5576288A
(en)
*
|
1989-04-27 |
1996-11-19 |
The Salk Institute For Biological Studies |
Fibroblast growth factor conjugates
|
IL95031A
(en)
|
1989-07-18 |
2007-03-08 |
Amgen Inc |
A method of producing a recombinant human necrotic factor absorber
|
AU638043B2
(en)
*
|
1989-07-20 |
1993-06-17 |
Novartis Ag |
Labeled polypeptide derivatives
|
US5208323A
(en)
*
|
1989-08-10 |
1993-05-04 |
Universite Laval |
Coupling of an anti-tumor to an antibody using glutaraldehyde preactivated anti-tumor agent
|
US5977307A
(en)
*
|
1989-09-07 |
1999-11-02 |
Alkermes, Inc. |
Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
|
US5527527A
(en)
*
|
1989-09-07 |
1996-06-18 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
|
US6329508B1
(en)
|
1989-09-07 |
2001-12-11 |
Alkermes, Inc. |
Transferrin receptor reactive chimeric antibodies
|
US5182107A
(en)
*
|
1989-09-07 |
1993-01-26 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
|
US5672683A
(en)
*
|
1989-09-07 |
1997-09-30 |
Alkermes, Inc. |
Transferrin neuropharmaceutical agent fusion protein
|
JPH04505019A
(ja)
*
|
1989-10-23 |
1992-09-03 |
シェリング・コーポレーション |
ガンマインターフェロンのポリペプチド性阻害剤
|
DE69132581T3
(de)
*
|
1990-03-02 |
2008-07-17 |
Boston Medical Center Corp., Boston |
Verbesserte chimäre toxine
|
US6552170B1
(en)
|
1990-04-06 |
2003-04-22 |
Amgen Inc. |
PEGylation reagents and compounds formed therewith
|
US5137877B1
(en)
*
|
1990-05-14 |
1996-01-30 |
Bristol Myers Squibb Co |
Bifunctional linking compounds conjugates and methods for their production
|
EP0485563B1
(de)
*
|
1990-05-30 |
1994-12-21 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Polyethersubstituierte tumormittel
|
IL98528A0
(en)
*
|
1990-06-21 |
1992-07-15 |
Merck & Co Inc |
Pharmaceutical compositions containing hybrid for killing bladder cancer cells
|
EP0537229A1
(de)
*
|
1990-07-05 |
1993-04-21 |
Akzo Nobel N.V. |
Gegen rezeptoren gerichtete toxin-konjugate
|
US5478804A
(en)
*
|
1990-09-19 |
1995-12-26 |
The Salk Institute For Biological Studies |
Treatment of tumorigenic pathophysiological conditions with FGF-cytoxic conjugates
|
ATE152917T1
(de)
*
|
1990-09-28 |
1997-05-15 |
Neorx Corp |
Polymere träger zur freisetzung kovalent gebundener wirkstoffe
|
US5431899A
(en)
*
|
1991-02-04 |
1995-07-11 |
University Of Saskatchewan |
Rotavirus VP6 as a diagnostic and targeting agent
|
US5464753A
(en)
*
|
1991-03-08 |
1995-11-07 |
Univ Illinois |
Purification and manipulation of bone marrow and blood cells on the basis of P-glycoprotein expression
|
SG47099A1
(en)
*
|
1991-03-15 |
1998-03-20 |
Amgen Boulder Inc |
Pegylation of polypeptides
|
JPH07500315A
(ja)
*
|
1991-05-10 |
1995-01-12 |
セルトリックス ファーマシューティカルズ,インコーポレイテッド |
骨成長因子の標的送達
|
EP0529175B1
(de)
*
|
1991-07-22 |
1995-08-09 |
BRACCO International B.V. |
Anwendung von Chelaten von Konjugaten mit paramagnetischen Metallen für Targetting
|
NZ244306A
(en)
*
|
1991-09-30 |
1995-07-26 |
Boehringer Ingelheim Int |
Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
|
US5981273A
(en)
*
|
1991-09-30 |
1999-11-09 |
Boehringer Ingelheim Int'l. Gmbh |
Composition comprising an endosomolytic agent for introducing nucleic acid complexes into higher eucaryotic cells
|
US5521291A
(en)
*
|
1991-09-30 |
1996-05-28 |
Boehringer Ingelheim International, Gmbh |
Conjugates for introducing nucleic acid into higher eucaryotic cells
|
US5922859A
(en)
*
|
1992-02-01 |
1999-07-13 |
Boehringer Ingelheim International Gmbh |
Complexes containing nucleic acid which can be taken-up by endocytosis into higher eukaryotic cells
|
ES2149768T3
(es)
*
|
1992-03-25 |
2000-11-16 |
Immunogen Inc |
Conjugados de agentes enlazantes de celulas derivados de cc-1065.
|
US5679350A
(en)
*
|
1992-05-28 |
1997-10-21 |
The University Of Toledo |
Method of delivery of a medicament to a cancer cell using a pathway of plasminogen activator material
|
ES2143504T3
(es)
*
|
1992-05-28 |
2000-05-16 |
Univ Toledo |
Uso de un material citotoxico acoplado a un material inhibidor del activador plasminogeno para la produccion de un medicamento para el tratamiento de celulas cancerigenas.
|
AU685058B2
(en)
*
|
1992-06-16 |
1998-01-15 |
Selective Genetics, Inc. |
Recombinant production of saporin-containing proteins
|
US5393737A
(en)
*
|
1992-08-20 |
1995-02-28 |
Health Research, Inc. |
Cytotoxic drug conjugates for treatment of neoplastic diseases
|
AU5125693A
(en)
*
|
1992-09-03 |
1994-03-29 |
Regents Of The University Of California, The |
Dorsal tissue affecting factor and compositions
|
US5466672A
(en)
*
|
1992-12-04 |
1995-11-14 |
Ophidian Pharmaceuticals, Inc. |
Therapeutic use of clostridium difficile toxin A
|
US6001364A
(en)
|
1993-05-05 |
1999-12-14 |
Gryphon Sciences |
Hetero-polyoxime compounds and their preparation by parallel assembly
|
US6174530B1
(en)
|
1993-05-05 |
2001-01-16 |
Gryphon Sciences |
Homogeneous polyoxime compositions and their preparation by parallel assembly
|
ATE191148T1
(de)
|
1993-05-05 |
2000-04-15 |
Keith Rose |
Polyoximverbindungen und deren herstellung
|
US6214345B1
(en)
|
1993-05-14 |
2001-04-10 |
Bristol-Myers Squibb Co. |
Lysosomal enzyme-cleavable antitumor drug conjugates
|
US5502037A
(en)
*
|
1993-07-09 |
1996-03-26 |
Neuromed Technologies, Inc. |
Pro-cytotoxic drug conjugates for anticancer therapy
|
US6491905B1
(en)
*
|
1993-09-14 |
2002-12-10 |
The Uab Research Foundation |
Recombinant bacterial cells for delivery of PNP to tumor cells
|
DE69425356T2
(de)
*
|
1993-09-22 |
2002-04-18 |
Hoechst Ag |
Pro-Prodrugs, ihre Herstellung und Anwendung
|
US5879656A
(en)
*
|
1993-10-26 |
1999-03-09 |
Thomas Jefferson University |
Methods of treating metastatic colorectal cancer with ST receptor binding compounds
|
US5962220A
(en)
*
|
1993-10-26 |
1999-10-05 |
Thomas Jefferson University |
Compositions that specifically bind to colorectal cells and methods of using the same
|
US7097839B1
(en)
*
|
1993-10-26 |
2006-08-29 |
Thomas Jefferson University |
ST receptor binding compounds and methods of using the same
|
ES2237750T3
(es)
*
|
1993-12-09 |
2005-08-01 |
Centro De Inmunologia Molecular |
Vacuna que comprende factor de crecimiento epidermico autologo humano y su uso.
|
US6551618B2
(en)
*
|
1994-03-15 |
2003-04-22 |
University Of Birmingham |
Compositions and methods for delivery of agents for neuronal regeneration and survival
|
US5587459A
(en)
*
|
1994-08-19 |
1996-12-24 |
Regents Of The University Of Minnesota |
Immunoconjugates comprising tyrosine kinase inhibitors
|
US5911995A
(en)
*
|
1994-08-19 |
1999-06-15 |
Regents Of The University Of Minnesota |
EGF-genistein conjugates for the treatment of cancer
|
DE4433890C2
(de)
*
|
1994-09-22 |
1999-02-18 |
Deutsches Krebsforsch |
Konjugat aus einem Wirkstoff und einem nicht als körperfremd angesehenen, nativen Protein
|
AU708529B2
(en)
*
|
1994-11-10 |
1999-08-05 |
University Of Kentucky Research Foundation, The |
Implantable refillable controlled release device to deliver drugs directly to an internal portion of the body
|
US5766899A
(en)
*
|
1995-02-27 |
1998-06-16 |
Board Of Regents , The University Of Texas System |
Targeted nucleic acid delivery into liver cells
|
US6015555A
(en)
*
|
1995-05-19 |
2000-01-18 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
|
US20030119724A1
(en)
*
|
1995-11-22 |
2003-06-26 |
Ts`O Paul O.P. |
Ligands to enhance cellular uptake of biomolecules
|
JP2000503639A
(ja)
*
|
1995-12-22 |
2000-03-28 |
ブリストル―マイヤーズ スクイブ カンパニー |
分枝ヒドラゾンのリンカー類
|
US20050025740A1
(en)
*
|
1996-01-05 |
2005-02-03 |
Keith Rose |
Polyoxime compounds and their preparation
|
NZ332234A
(en)
|
1996-03-12 |
2000-06-23 |
Pg Txl Company Lp |
Water soluble paclitaxel prodrugs formed by conjugating paclitaxel or docetaxel with a polyglutamic acid polymer and use for treating cancer
|
US6441025B2
(en)
*
|
1996-03-12 |
2002-08-27 |
Pg-Txl Company, L.P. |
Water soluble paclitaxel derivatives
|
US6030941A
(en)
*
|
1996-05-01 |
2000-02-29 |
Avi Biopharma, Inc. |
Polymer composition for delivering substances in living organisms
|
TW555765B
(en)
|
1996-07-09 |
2003-10-01 |
Amgen Inc |
Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
|
US5952294A
(en)
*
|
1996-07-31 |
1999-09-14 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Peptidyl prodrugs and methods of making and using the same
|
DE19636889A1
(de)
*
|
1996-09-11 |
1998-03-12 |
Felix Dr Kratz |
Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel
|
US6080383A
(en)
*
|
1997-01-13 |
2000-06-27 |
Rose; Samuel |
Method and composition for the treatment of cancer by the enzymatic conversion of soluble radioactive toxic agents into radioactive toxic precipitates in the cancer
|
AU7124598A
(en)
*
|
1997-04-18 |
1998-11-13 |
Access Pharmaceuticals, Inc. |
Polymer-platinum compounds
|
US5965118A
(en)
*
|
1997-04-18 |
1999-10-12 |
Access Pharmaceuticals, Inc. |
Polymer-platinum compounds
|
US6548482B1
(en)
|
1997-05-05 |
2003-04-15 |
Mayo Foundation For Medical Education And Research |
Treatment of osteoporosis
|
US6916790B2
(en)
|
1997-05-05 |
2005-07-12 |
Mayo Foundation For Medical Education And Research |
Treatment of osteoporosis
|
DE69835878T2
(de)
*
|
1997-05-05 |
2007-04-26 |
Mayo Foundation For Medical Education And Research, Rochester |
IGFIIE/ IGFBP2 Komplex
|
US6030997A
(en)
*
|
1998-01-21 |
2000-02-29 |
Eilat; Eran |
Acid labile prodrugs
|
US6866837B2
(en)
|
1998-06-05 |
2005-03-15 |
Mallinckrodt Inc. |
Radiolabeled peptides for the diagnosis and treatment of breast and prostate tumors and metastases of such tumors
|
CA2338000C
(en)
*
|
1998-07-17 |
2009-12-15 |
The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Water-soluble 4-thio-maleimido derivatives and methods for their production
|
US6747055B1
(en)
|
1998-07-17 |
2004-06-08 |
The United States Of America As Represented By The Department Of Health And Human Services |
Water-soluble drugs and methods for their production
|
GB9904582D0
(en)
*
|
1999-02-26 |
1999-04-21 |
Nycomed Imaging As |
Process
|
US7018654B2
(en)
*
|
1999-03-05 |
2006-03-28 |
New River Pharmaceuticals Inc. |
Pharmaceutical composition containing an active agent in an amino acid copolymer structure
|
US6716452B1
(en)
*
|
2000-08-22 |
2004-04-06 |
New River Pharmaceuticals Inc. |
Active agent delivery systems and methods for protecting and administering active agents
|
US7060708B2
(en)
*
|
1999-03-10 |
2006-06-13 |
New River Pharmaceuticals Inc. |
Active agent delivery systems and methods for protecting and administering active agents
|
US20010041189A1
(en)
*
|
1999-04-13 |
2001-11-15 |
Jingya Xu |
Poly(dipeptide) as a drug carrier
|
US6706892B1
(en)
|
1999-09-07 |
2004-03-16 |
Conjuchem, Inc. |
Pulmonary delivery for bioconjugation
|
US20030054977A1
(en)
*
|
1999-10-12 |
2003-03-20 |
Cell Therapeutics, Inc. |
Manufacture of polyglutamate-therapeutic agent conjugates
|
US7067111B1
(en)
*
|
1999-10-25 |
2006-06-27 |
Board Of Regents, University Of Texas System |
Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
|
US20020077290A1
(en)
*
|
2000-03-17 |
2002-06-20 |
Rama Bhatt |
Polyglutamic acid-camptothecin conjugates and methods of preparation
|
DE60140865D1
(de)
*
|
2000-03-27 |
2010-02-04 |
Univ Jefferson |
Zusammensetzungen und methoden zur identifizierung von krebszellen
|
CA2410906C
(en)
*
|
2000-06-02 |
2012-10-02 |
Board Of Regents, The University Of Texas System |
Ethylenedicysteine (ec)-drug conjugates
|
CA2414650A1
(en)
*
|
2000-06-30 |
2002-01-10 |
Board Of Regents, The University Of Texas System |
Isolation of a cell-specific internalizing peptide that infiltrates tumor tissue for targeted drug delivery
|
US7163918B2
(en)
|
2000-08-22 |
2007-01-16 |
New River Pharmaceuticals Inc. |
Iodothyronine compositions
|
US20020099013A1
(en)
*
|
2000-11-14 |
2002-07-25 |
Thomas Piccariello |
Active agent delivery systems and methods for protecting and administering active agents
|
HUP0303719A2
(hu)
*
|
2000-10-16 |
2004-03-01 |
Neopharm, Inc. |
Mitoxantron hatóanyag-tartalmú liposzómás gyógyszerkészítmények és eljárás az előállításukra
|
US8394813B2
(en)
*
|
2000-11-14 |
2013-03-12 |
Shire Llc |
Active agent delivery systems and methods for protecting and administering active agents
|
AU2002217980A1
(en)
|
2000-12-01 |
2002-06-11 |
Cell Works Inc. |
Conjugates of glycosylated/galactosylated peptide
|
CU22999A1
(es)
|
2001-12-04 |
2004-10-12 |
Centro Inmunologia Molecular |
Método de tratamiento de enfermedades malignas e infecciosas crónicas
|
US20030003048A1
(en)
*
|
2001-04-26 |
2003-01-02 |
Chun Li |
Diagnostic imaging compositions, their methods of synthesis and use
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
ES2552281T3
(es)
|
2001-05-11 |
2015-11-26 |
Ludwig Institute For Cancer Research Ltd. |
Proteínas de unión específica y usos de las mismas
|
WO2002094271A1
(en)
*
|
2001-05-15 |
2002-11-28 |
Faulk Pharmaceuticals, Inc. |
Targeted delivery of bioaffecting compounds for the treatment of cancer
|
CA2447335C
(en)
*
|
2001-05-15 |
2011-01-04 |
Faulk Pharmaceuticals, Inc. |
Targeted delivery of drugs for the treatment of viral infections
|
WO2003000711A1
(en)
*
|
2001-06-22 |
2003-01-03 |
The University Of British Columbia |
Antimitotic eleuthesides
|
US20060014697A1
(en)
*
|
2001-08-22 |
2006-01-19 |
Travis Mickle |
Pharmaceutical compositions for prevention of overdose or abuse
|
US7375082B2
(en)
*
|
2002-02-22 |
2008-05-20 |
Shire Llc |
Abuse-resistant hydrocodone compounds
|
US7169752B2
(en)
*
|
2003-09-30 |
2007-01-30 |
New River Pharmaceuticals Inc. |
Compounds and compositions for prevention of overdose of oxycodone
|
US7338939B2
(en)
*
|
2003-09-30 |
2008-03-04 |
New River Pharmaceuticals Inc. |
Abuse-resistant hydrocodone compounds
|
US20070066537A1
(en)
*
|
2002-02-22 |
2007-03-22 |
New River Pharmaceuticals Inc. |
Compounds and compositions for prevention of overdose of oxycodone
|
US20030109432A1
(en)
*
|
2001-12-10 |
2003-06-12 |
Zuo William W. |
Anticancer polypeptide-metal complexes and compositions, methods of making, and methods of using same
|
US7261875B2
(en)
*
|
2001-12-21 |
2007-08-28 |
Board Of Regents, The University Of Texas System |
Dendritic poly (amino acid) carriers and methods of use
|
RU2196604C1
(ru)
*
|
2001-12-21 |
2003-01-20 |
Северин Евгений Сергеевич |
Полипептид, являющийся аналогом рецепторсвязывающего фрагмента эпидермального фактора роста с 21-й по 31-ю аминокислоту, его конъюгат с доксорубицином и фармацевтическая композиция на его основе
|
ES2500117T3
(es)
*
|
2002-02-22 |
2014-09-30 |
Shire Llc |
Novedosos compuestos farmacéuticos de liberación sostenida para prevenir el abuso de sustancias controladas
|
US7105486B2
(en)
*
|
2002-02-22 |
2006-09-12 |
New River Pharmaceuticals Inc. |
Abuse-resistant amphetamine compounds
|
EP2266590A3
(de)
|
2002-02-22 |
2011-04-20 |
Shire LLC |
Wirkstoff-Abgabesystem und Verfahren zum Schutz und zur Verabreichung von Wirkstoffen
|
US7700561B2
(en)
*
|
2002-02-22 |
2010-04-20 |
Shire Llc |
Abuse-resistant amphetamine prodrugs
|
IL163668A0
(en)
*
|
2002-02-22 |
2005-12-18 |
New River Pharmaceuticals Inc |
Use of peptide-drug conjugation to reduce inter-subject variability ofdrug serum levels
|
US7659253B2
(en)
*
|
2002-02-22 |
2010-02-09 |
Shire Llc |
Abuse-resistant amphetamine prodrugs
|
DK1551372T3
(en)
|
2002-09-20 |
2018-07-23 |
Alpharma Pharmaceuticals Llc |
SEQUERATION SUBSTANCES AND RELATED COMPOSITIONS AND PROCEDURES
|
CN101985443A
(zh)
*
|
2002-11-07 |
2011-03-16 |
得克萨斯大学体系董事会 |
乙二半胱氨酸(ec)-药物结合物、组合物及用于组织特异性疾病显像的方法
|
JP4740862B2
(ja)
|
2003-05-07 |
2011-08-03 |
インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション |
合金化された半導体量子ドットおよび合金化された濃度勾配量子ドット、これらの量子ドットを含むシリーズ、ならびにこれらに関する方法
|
KR101170840B1
(ko)
*
|
2003-05-29 |
2012-08-03 |
샤이어 엘엘씨 |
남용 방지성 암페타민 화합물
|
WO2005016368A2
(en)
*
|
2003-08-19 |
2005-02-24 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Use of phosphophoryn for inducing biomineralization and bone regeneration
|
EP1675555A4
(de)
*
|
2003-09-30 |
2011-03-09 |
Shire Llc |
Pharmazeutische zusammensetzungen zur prävention einer überdosierung oder von missbrauch
|
AU2004284075A1
(en)
|
2003-10-22 |
2005-05-06 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto
|
EP1694325A4
(de)
|
2003-12-03 |
2009-03-25 |
Univ New Jersey Med |
Verfahren zur prävention des überlebens von retroviralen zellen und zur hemmung der bildung von infektiösen retroviren
|
US9050378B2
(en)
*
|
2003-12-10 |
2015-06-09 |
Board Of Regents, The University Of Texas System |
N2S2 chelate-targeting ligand conjugates
|
CA2548457C
(en)
*
|
2003-12-10 |
2010-08-24 |
Toudai Tlo, Ltd. |
Coordination complex of diaminocyclohexaneplatinum(ii) with block copolymer containing poly(carboxylic acid) segment and antitumor agent comprising the same
|
DK2206728T3
(en)
|
2004-04-07 |
2018-04-23 |
Rinat Neuroscience Corp |
METHODS OF TREATING BONE CANCER PAIN BY SUBMITTING A NERVOUS FACTOR-ANTAGONISTIC ANTIBODY
|
US20060036084A1
(en)
*
|
2004-08-04 |
2006-02-16 |
Lianhua Qu |
Conglomerated semiconductor nanocrystals
|
US8454927B2
(en)
*
|
2004-08-04 |
2013-06-04 |
Crystalplex Corporation |
Alloyed semiconductor nanocrystals
|
EP1897900B1
(de)
*
|
2005-06-09 |
2013-08-07 |
NanoCarrier Co., Ltd. |
Verfahren zur herstellung einer polymerisierten koordinationsverbindung eines platinkomplexes
|
WO2007055902A1
(en)
|
2005-11-03 |
2007-05-18 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Immunogenic peptides and methods of use for treating and preventing cancer
|
JP5237821B2
(ja)
|
2005-12-05 |
2013-07-17 |
日東電工株式会社 |
ポリグルタミン酸−アミノ酸結合体および方法
|
US7820174B2
(en)
|
2006-02-24 |
2010-10-26 |
The United States Of America As Represented By The Department Of Health And Human Services |
T cell receptors and related materials and methods of use
|
US9107863B2
(en)
|
2006-03-27 |
2015-08-18 |
The Buck Institute For Age Reasearch |
Reagents and methods for cancer treatment and prevention
|
US8758723B2
(en)
|
2006-04-19 |
2014-06-24 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods for cellular imaging and therapy
|
CN101677963B
(zh)
|
2006-06-19 |
2012-05-30 |
奥尔制药公司 |
药物组合物
|
WO2008039818A2
(en)
|
2006-09-26 |
2008-04-03 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Modified t cell receptors and related materials and methods
|
US10925977B2
(en)
|
2006-10-05 |
2021-02-23 |
Ceil>Point, LLC |
Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
|
WO2008070357A2
(en)
|
2006-10-31 |
2008-06-12 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Smoothened polypeptides and methods of use
|
AU2008206442B2
(en)
|
2007-01-12 |
2012-10-18 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
gp100-specific T cell receptors and related materials and methods of use
|
US9090693B2
(en)
*
|
2007-01-25 |
2015-07-28 |
Dana-Farber Cancer Institute |
Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
|
US20080181852A1
(en)
*
|
2007-01-29 |
2008-07-31 |
Nitto Denko Corporation |
Multi-functional Drug Carriers
|
MX2009009782A
(es)
|
2007-03-15 |
2010-09-10 |
Ludwig Inst Cancer Res |
Metodo de tratamiento que utiliza anticuerpos egfr e inhibidores de src y formulaciones relacionadas.
|
CN101674852A
(zh)
*
|
2007-04-10 |
2010-03-17 |
日东电工株式会社 |
多功能聚谷氨酸盐药物载体
|
EP2155253A2
(de)
*
|
2007-05-09 |
2010-02-24 |
Nitto Denko Corporation |
Polyglutamatkonjugate und polyglutamat-aminosäure-konjugate mit mehreren wirkstoffen
|
US20080279782A1
(en)
*
|
2007-05-09 |
2008-11-13 |
Nitto Denko Corporation |
Polymers conjugated with platinum drugs
|
KR20100017540A
(ko)
*
|
2007-05-09 |
2010-02-16 |
닛토덴코 가부시키가이샤 |
소수성 화합물 및 폴리아미노산 콘쥬게이트를 포함하는 조성물
|
WO2009023265A1
(en)
|
2007-08-14 |
2009-02-19 |
Ludwig Institute For Cancer Research |
Monoclonal antibody 175 targeting the egf receptor and derivatives and uses thereof
|
US20100256098A1
(en)
*
|
2007-08-31 |
2010-10-07 |
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services |
Compounds for inhibiting wip1, prodrugs and compositions thereof, and related methods
|
MX2010009670A
(es)
*
|
2008-03-06 |
2010-09-22 |
Nitto Denko Corp |
Conjugados de paclitaxel polimericos y metodos para tratamiento de cancer.
|
WO2010075417A1
(en)
|
2008-12-23 |
2010-07-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Survivin specific t cell receptor for treating cancer
|
WO2010075303A1
(en)
|
2008-12-23 |
2010-07-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Splicing factors with a puf protein rna-binding domain and a splicing effector domain and uses of same
|
US8785601B2
(en)
|
2009-01-28 |
2014-07-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
T cell receptors and related materials and methods of use
|
US9616245B2
(en)
*
|
2009-03-16 |
2017-04-11 |
Rajah Vijay Kumar |
Method of treating cells with drug and radiation according to proton density
|
EP2411038B1
(de)
|
2009-03-27 |
2016-12-28 |
Van Andel Research Institute |
Parathryoidhormonpeptide und parathyroidhormonbezogene proteinpeptide sowie anwendungsverfahren dafür
|
US8603814B2
(en)
*
|
2009-07-20 |
2013-12-10 |
Rutgers The State University Of New Jersey |
Method of inhibiting nonsense-mediated mRNA decay
|
US9849146B2
(en)
|
2009-07-20 |
2017-12-26 |
Rutgers, The State University Of New Jersey |
Inhibition of nonsense mediated mRNA decay by drugs that prevent hypusination of eukaryotic initiation factor 5A
|
WO2011032099A1
(en)
|
2009-09-11 |
2011-03-17 |
The Board Of Trustees Of The University Of Illinois |
Methods of treating diastolic dysfunction and related conditions
|
US20110076232A1
(en)
*
|
2009-09-29 |
2011-03-31 |
Ludwig Institute For Cancer Research |
Specific binding proteins and uses thereof
|
WO2011041093A1
(en)
|
2009-10-01 |
2011-04-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
|
EP2488637B1
(de)
|
2009-10-16 |
2015-12-23 |
The University Of British Columbia |
Hemmer für phosphatase-tensinhomolog-zusammensetzungen sowie verwendungen davon und verfahren dafür
|
WO2011056572A1
(en)
|
2009-10-27 |
2011-05-12 |
The Board Of Trustees Of The University Of Illinois |
Methods of diagnosing diastolic dysfunction
|
US20120251514A1
(en)
|
2009-11-13 |
2012-10-04 |
University Health Network |
Modulated programmed death ligand-1
|
US8703701B2
(en)
|
2009-12-18 |
2014-04-22 |
Indiana University Research And Technology Corporation |
Glucagon/GLP-1 receptor co-agonists
|
EP2528618A4
(de)
|
2010-01-27 |
2015-05-27 |
Univ Indiana Res & Tech Corp |
Glucagon-antagonisten- und gip-agonisten-konjugate sowie zusammensetzungen zur behandlung von stoffwechselerkrankungen und adipositas
|
WO2011116026A2
(en)
|
2010-03-15 |
2011-09-22 |
The Board Of Trustees Of The University Of Illinois |
Inhibitors of beta integrin-g protein alpha subunit binding interactions
|
ES2734889T3
(es)
|
2010-09-21 |
2019-12-12 |
Us Health |
Receptores de células T anti-SSX-2 y materiales relacionados y métodos de uso
|
WO2012054825A1
(en)
|
2010-10-22 |
2012-04-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mage-a3 t cell receptors and related materials and methods of use
|
EP2655401B1
(de)
|
2010-12-20 |
2016-03-09 |
The Regents of the University of Michigan |
Hemmer der bindeinteraktion des epidermalen wachstumsfaktor-rezeptor-wärmeschock-proteins 90
|
MA34885B1
(fr)
|
2010-12-22 |
2014-02-01 |
Indiana Unversity Res And Technology Corp |
Analogues du glucagon presentant una ctivite de recepteur de gip
|
CN102675422B
(zh)
|
2011-03-15 |
2014-02-05 |
天津托普泰克生物科技有限公司 |
抗乙型肝炎病毒x蛋白多肽药物
|
EP2694549B1
(de)
|
2011-04-08 |
2018-08-15 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Chimäre antigenrezeptoren des anti-egf-rezeptors variante iii und ihre verwendung zur behandlung von krebs
|
CN102746378B
(zh)
|
2011-04-22 |
2014-10-22 |
天津托普泰克生物科技有限公司 |
抗脂肪酸合成酶多肽及其应用
|
CN103748107B
(zh)
|
2011-06-09 |
2020-06-02 |
美利坚合众国, 由健康及人类服务部部长代表 |
具有免疫原性较小的t细胞和/或b细胞表位的假单胞菌外毒素a
|
US9156902B2
(en)
|
2011-06-22 |
2015-10-13 |
Indiana University Research And Technology Corporation |
Glucagon/GLP-1 receptor co-agonists
|
IL290105B2
(en)
|
2011-09-15 |
2024-04-01 |
Us Health |
MAGE-recognizing T cell receptors are restricted to 1HLA–A or HLA–CW7
|
EP2755993B1
(de)
|
2011-09-16 |
2017-11-08 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Pseudomonas exotoxin a mit weniger immunogenen b-zellepitopen
|
CA2851795C
(en)
|
2011-10-20 |
2018-11-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-cd22 chimeric antigen receptors
|
CA2847246A1
(en)
|
2011-11-17 |
2013-05-23 |
Indiana University Research And Technology Corporation |
Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
|
AU2013235726B2
(en)
|
2012-03-23 |
2017-04-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mesothelin chimeric antigen receptors
|
CA2869562C
(en)
|
2012-04-11 |
2023-09-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric antigen receptors targeting b-cell maturation antigen
|
WO2013177247A1
(en)
|
2012-05-22 |
2013-11-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Murine anti-ny-eso-1 t cell receptors
|
CN104619350A
(zh)
|
2012-06-14 |
2015-05-13 |
Ambrx公司 |
结合到核受体配体多肽的抗psma抗体
|
CA2877358A1
(en)
|
2012-06-21 |
2013-12-27 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting gip receptor activity
|
KR20150039748A
(ko)
|
2012-06-21 |
2015-04-13 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
Gip 수용체 활성을 나타내는 글루카곤의 유사체들
|
DK3636665T3
(da)
|
2012-09-14 |
2022-10-03 |
Us Health |
T-cellereceptorer, som genkender mhc klasse ii-begrænset mage-a3
|
CN104822705B
(zh)
|
2012-10-24 |
2019-07-12 |
美国卫生和人力服务部 |
M971嵌合抗原受体
|
US9790282B2
(en)
|
2013-03-25 |
2017-10-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
|
WO2014205187A1
(en)
|
2013-06-20 |
2014-12-24 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Cytolethal distending toxin subunit b conjugated or fused to bacillus anthracis toxin lethal factor
|
US9822162B2
(en)
|
2013-07-15 |
2017-11-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-human papillomavirus 16 E6 T cell receptors
|
US9388222B2
(en)
|
2013-10-06 |
2016-07-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Modified Pseudomonas exotoxin A
|
SG11201604565WA
(en)
|
2013-12-06 |
2016-07-28 |
Us Health |
Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using same
|
CN113046312A
(zh)
|
2014-04-23 |
2021-06-29 |
朱诺治疗学股份有限公司 |
分离、培养和遗传工程改造用于过继治疗的免疫细胞群的方法
|
JP6742991B2
(ja)
|
2014-05-29 |
2020-08-19 |
アメリカ合衆国 |
抗ヒトパピローマウイルス16 e7 t細胞受容体
|
CN106536564B
(zh)
|
2014-06-02 |
2021-08-31 |
美国卫生和人力服务部 |
靶向cd-19的嵌合抗原受体
|
MA40253A
(fr)
|
2014-07-15 |
2017-05-24 |
Juno Therapeutics Inc |
Cellules modifiées pour thérapie cellulaire adoptive
|
TWI751102B
(zh)
|
2014-08-28 |
2022-01-01 |
美商奇諾治療有限公司 |
對cd19具專一性之抗體及嵌合抗原受體
|
ES2879612T3
(es)
|
2014-10-20 |
2021-11-22 |
Juno Therapeutics Inc |
Métodos y composiciones para dosificación en terapia celular adoptiva
|
US20190030071A1
(en)
|
2014-11-03 |
2019-01-31 |
IMMURES S.r.I. |
T cell receptors
|
MA40318A
(fr)
|
2014-11-05 |
2017-09-13 |
Juno Therapeutics Inc |
Procédés de transduction et de traitement de cellules
|
MX2017007138A
(es)
|
2014-12-03 |
2017-08-28 |
Juno Therapeutics Inc |
Metodos y composiciones para terapia celular adoptiva.
|
US20160208018A1
(en)
|
2015-01-16 |
2016-07-21 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for ror1
|
WO2016166568A1
(en)
|
2015-04-16 |
2016-10-20 |
Juno Therapeutics Gmbh |
Methods, kits and apparatus for expanding a population of cells
|
CA2986060A1
(en)
|
2015-05-29 |
2016-12-08 |
Valerie Odegard |
Composition and methods for regulating inhibitory interactions in genetically engineered cells
|
MA42895A
(fr)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
Cellules modifiées pour thérapie cellulaire adoptive
|
CN116875635A
(zh)
|
2015-10-22 |
2023-10-13 |
朱诺治疗学有限公司 |
用于转导的方法、反应剂盒、反应剂和设备
|
MA45489A
(fr)
|
2015-10-22 |
2018-08-29 |
Juno Therapeutics Gmbh |
Procédés de culture de cellules, kits et appareil associés
|
MA45488A
(fr)
|
2015-10-22 |
2018-08-29 |
Juno Therapeutics Gmbh |
Procédés, kits et appareil de culture de cellules
|
US11020429B2
(en)
|
2015-11-05 |
2021-06-01 |
Juno Therapeutics, Inc. |
Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
|
MA44314A
(fr)
|
2015-11-05 |
2018-09-12 |
Juno Therapeutics Inc |
Récepteurs chimériques contenant des domaines induisant traf, et compositions et méthodes associées
|
AU2016363025B2
(en)
|
2015-12-03 |
2021-04-08 |
Juno Therapeutics, Inc. |
Modified chimeric receptors and related compositions and methods
|
MA43377A
(fr)
|
2015-12-04 |
2021-05-19 |
Hutchinson Fred Cancer Res |
Méthodes et compositions liées à la toxicité associée à la thérapie cellulaire
|
EP3430549A1
(de)
|
2016-03-16 |
2019-01-23 |
Juno Therapeutics, Inc. |
Verfahren zum adaptiven design eines behandlungsplans und ähnlicher behandlungen
|
EP3430548A1
(de)
|
2016-03-16 |
2019-01-23 |
Juno Therapeutics, Inc. |
Verfahren zur bestimmung der dosierung eines therapeutikums und verwandte behandlungen
|
EP4015536A1
(de)
|
2016-03-22 |
2022-06-22 |
Seattle Children's Hospital (DBA Seattle Children's Research Institute) |
Frühinterventionsverfahren zur vermeidung oder verbesserung von toxizität
|
WO2017193107A2
(en)
|
2016-05-06 |
2017-11-09 |
Juno Therapeutics, Inc. |
Genetically engineered cells and methods of making the same
|
CA3026453A1
(en)
|
2016-06-03 |
2017-12-07 |
Memorial Sloan-Kettering Cancer Center |
Adoptive cell therapies as early treatment options
|
MA45341A
(fr)
|
2016-06-06 |
2019-04-10 |
Hutchinson Fred Cancer Res |
Procédés de traitement de malignités de lymphocytes b au moyen d'une thérapie cellulaire adoptive
|
MA45491A
(fr)
|
2016-06-27 |
2019-05-01 |
Juno Therapeutics Inc |
Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
|
CA3028002A1
(en)
|
2016-06-27 |
2018-01-04 |
Juno Therapeutics, Inc. |
Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
|
WO2018005759A1
(en)
|
2016-07-01 |
2018-01-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Inhibitor of heme degradation for use to improve antibiotic treatment of mycobacterium tuberculosis infection
|
MX2019001185A
(es)
|
2016-07-29 |
2019-10-21 |
Juno Therapeutics Inc |
Polipeptidos inmunomoduladores y composiciones y metodos relacionados.
|
CN110139873A
(zh)
|
2016-10-03 |
2019-08-16 |
朱诺治疗学股份有限公司 |
Hpv特异性结合分子
|
CN110494565A
(zh)
|
2016-12-02 |
2019-11-22 |
朱诺治疗学股份有限公司 |
工程化b细胞及相关组合物和方法
|
US20200078400A1
(en)
|
2016-12-03 |
2020-03-12 |
Juno Therapeutics, Inc. |
Methods for determining car-t cells dosing
|
CA3045508A1
(en)
|
2016-12-03 |
2018-06-07 |
Juno Therapeutics, Inc. |
Methods for modulation of car-t cells
|
JP2019536461A
(ja)
|
2016-12-05 |
2019-12-19 |
ジュノー セラピューティクス インコーポレイテッド |
養子細胞療法のための操作細胞の産生
|
AU2018207305A1
(en)
|
2017-01-10 |
2019-07-25 |
Juno Therapeutics, Inc. |
Epigenetic analysis of cell therapy and related methods
|
CN110418802A
(zh)
|
2017-01-20 |
2019-11-05 |
朱诺治疗学有限公司 |
细胞表面缀合物及相关的细胞组合物和方法
|
US11850262B2
(en)
|
2017-02-28 |
2023-12-26 |
Purdue Research Foundation |
Compositions and methods for CAR T cell therapy
|
WO2018187791A1
(en)
|
2017-04-07 |
2018-10-11 |
Juno Therapeutics, Inc |
Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods
|
BR112019022356A2
(pt)
|
2017-04-27 |
2020-05-26 |
Juno Therapeutics Gmbh |
Reagentes de partícula oligoméricos e métodos de uso dos mesmos
|
MA48781A
(fr)
|
2017-06-02 |
2020-04-08 |
Juno Therapeutics Inc |
Articles de fabrication et procédés liés à la toxicité associée à la thérapie cellulaire
|
WO2018223101A1
(en)
|
2017-06-02 |
2018-12-06 |
Juno Therapeutics, Inc. |
Articles of manufacture and methods for treatment using adoptive cell therapy
|
CN109517820B
(zh)
|
2017-09-20 |
2021-09-24 |
北京宇繁生物科技有限公司 |
一种靶向HPK1的gRNA以及HPK1基因编辑方法
|
CA3080546A1
(en)
|
2017-10-03 |
2019-04-11 |
Juno Therapeutics, Inc. |
Hpv-specific binding molecules
|
US20230061455A1
(en)
|
2017-11-01 |
2023-03-02 |
Editas Medicine, Inc. |
Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy
|
MA50855A
(fr)
|
2017-11-01 |
2020-09-09 |
Juno Therapeutics Inc |
Procédé de génération de compositions thérapeutiques de cellules modifiées
|
KR20200116077A
(ko)
|
2017-11-01 |
2020-10-08 |
주노 쎄러퓨티크스 인코퍼레이티드 |
B 세포 성숙 항원에 특이적인 키메라 항원 수용체 및 암호화 폴리뉴클레오타이드
|
CA3080904A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
|
SG11202003657VA
(en)
|
2017-11-01 |
2020-05-28 |
Juno Therapeutics Inc |
Process for producing a t cell composition
|
US20230137729A1
(en)
|
2017-11-06 |
2023-05-04 |
Editas Medicine, Inc. |
Methods, compositions and components for crispr-cas9 editing of cblb in t cells for immunotherapy
|
CN111989106A
(zh)
|
2017-12-01 |
2020-11-24 |
朱诺治疗学股份有限公司 |
基因工程化细胞的给药和调节方法
|
KR20200109308A
(ko)
|
2017-12-08 |
2020-09-22 |
주노 쎄러퓨티크스 인코퍼레이티드 |
세포 요법을 위한 표현형 마커 및 관련 방법
|
MX2020005908A
(es)
|
2017-12-08 |
2020-10-07 |
Juno Therapeutics Inc |
Proceso para producir una composicion de celulas t modificadas.
|
BR112020011144A2
(pt)
|
2017-12-08 |
2020-11-17 |
Juno Therapeutics Inc |
formulação de meio livre de soro para o cultivo de células e métodos de uso da mesma
|
EP3724225A1
(de)
|
2017-12-15 |
2020-10-21 |
Juno Therapeutics, Inc. |
Anti-cct5-bindende moleküle und verfahren zur verwendung davon
|
TW201940182A
(zh)
|
2018-01-22 |
2019-10-16 |
美商安德賽特公司 |
Car t 細胞之使用方法
|
JP7383620B2
(ja)
|
2018-01-31 |
2023-11-20 |
セルジーン コーポレイション |
養子細胞療法およびチェックポイント阻害剤を使用する併用療法
|
WO2019170845A1
(en)
|
2018-03-09 |
2019-09-12 |
Ospedale San Raffaele S.R.L. |
Il-1 antagonist and toxicity induced by cell therapy
|
EP3775238A1
(de)
|
2018-04-05 |
2021-02-17 |
Juno Therapeutics, Inc. |
Verfahren zur herstellung von zellen, die einen rekombinanten rezeptor exprimieren, und verwandte zusammensetzungen
|
MX2020010461A
(es)
|
2018-04-05 |
2021-01-15 |
Juno Therapeutics Inc |
Linfocitos t que expresan un receptor recombinante, polinucleotidos y metodos relacionados.
|
CN112566698A
(zh)
|
2018-04-05 |
2021-03-26 |
朱诺治疗学股份有限公司 |
T细胞受体和表达该t细胞受体的工程化细胞
|
US20210163893A1
(en)
|
2018-08-09 |
2021-06-03 |
Juno Therapeutics, Inc. |
Processes for generating engineered cells and compositions thereof
|
US20210230671A1
(en)
|
2018-08-09 |
2021-07-29 |
Juno Therapeutics, Inc. |
Methods for assessing integrated nucleic acids
|
CA3110905A1
(en)
|
2018-08-31 |
2020-03-05 |
Invectys SA |
Chimeric antigen receptors against multiple hla-g isoforms
|
BR112021008133A2
(pt)
|
2018-10-31 |
2021-10-05 |
Juno Therapeutics Gmbh |
Métodos para seleção e estimulação de células e aparelhos para os mesmos
|
WO2020092854A2
(en)
|
2018-11-01 |
2020-05-07 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d)
|
WO2020092848A2
(en)
|
2018-11-01 |
2020-05-07 |
Juno Therapeutics, Inc. |
Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
|
EP3877054B1
(de)
|
2018-11-06 |
2023-11-01 |
Juno Therapeutics, Inc. |
Verfahren zur herstellung von genetisch veränderten t-zellen
|
JP2022513062A
(ja)
|
2018-11-16 |
2022-02-07 |
ジュノー セラピューティクス インコーポレイテッド |
B細胞悪性腫瘍を処置するために、操作されたt細胞を投薬する方法
|
JP2022513685A
(ja)
|
2018-11-30 |
2022-02-09 |
ジュノー セラピューティクス インコーポレイテッド |
養子細胞療法を用いた処置のための方法
|
MX2021006244A
(es)
|
2018-11-30 |
2021-09-10 |
Juno Therapeutics Inc |
Metodos de dosificacion y tratamiento de canceres de celulas b en terapia celular adoptiva.
|
PE20212198A1
(es)
|
2019-01-29 |
2021-11-16 |
Juno Therapeutics Inc |
Anticuerpos y receptores quimericos de antigenos especificos para receptor 1 huerfano tipo receptor tirosina-cinasa (ror1)
|
AU2020271123A1
(en)
|
2019-04-10 |
2021-11-25 |
Elevatebio Technologies, Inc. |
FLT3-specific chimeric antigen receptors and methods of using the same
|
AU2020265741A1
(en)
|
2019-05-01 |
2021-11-25 |
Editas Medicine, Inc. |
Cells expressing a recombinant receptor from a modified TGFBR2 Locus, related polynucleotides and methods
|
MX2021013223A
(es)
|
2019-05-01 |
2022-02-17 |
Juno Therapeutics Inc |
Celulas que expresan un receptor quimerico de un locus cd247 modificado, polinucleotidos relacionados y metodos.
|
CA3139032A1
(en)
|
2019-05-22 |
2020-11-26 |
Robert Alexander WESSELHOEFT |
Circular rna compositions and methods
|
CN112390894A
(zh)
|
2019-08-12 |
2021-02-23 |
广东东阳光药业有限公司 |
嵌合抗原受体及其应用
|
BR112022008023A2
(pt)
|
2019-10-30 |
2022-07-12 |
Juno Therapeutics Gmbh |
Dispositivos de seleção e/ou estimulação de células e métodos de uso
|
JP2023504737A
(ja)
|
2019-12-06 |
2023-02-06 |
ジュノー セラピューティクス インコーポレイテッド |
B細胞性悪性疾患を処置するための細胞療法と関連する毒性および奏効に関係する方法
|
WO2021154887A1
(en)
|
2020-01-28 |
2021-08-05 |
Juno Therapeutics, Inc. |
Methods for t cell transduction
|
KR20230009386A
(ko)
|
2020-04-10 |
2023-01-17 |
주노 쎄러퓨티크스 인코퍼레이티드 |
B-세포 성숙 항원을 표적화하는 키메라 항원 수용체로 조작된 세포 요법 관련 방법 및 용도
|
JP2023528215A
(ja)
|
2020-05-13 |
2023-07-04 |
ジュノー セラピューティクス インコーポレイテッド |
臨床応答に関連する特徴量の特定方法およびその使用
|
BR112022023554A2
(pt)
|
2020-05-19 |
2023-04-11 |
Orna Therapeutics Inc |
Composições e métodos de rna circular
|
WO2021260186A1
(en)
|
2020-06-26 |
2021-12-30 |
Juno Therapeutics Gmbh |
Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
|
WO2022098787A1
(en)
|
2020-11-04 |
2022-05-12 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
|
KR20230159851A
(ko)
|
2021-03-22 |
2023-11-22 |
주노 쎄러퓨티크스 인코퍼레이티드 |
치료 세포 조성물의 효력을 결정하는 방법
|
JP2024517863A
(ja)
|
2021-05-06 |
2024-04-23 |
ジュノ・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
細胞を刺激し、形質導入する方法
|
CN115404240A
(zh)
|
2021-05-28 |
2022-11-29 |
上海环码生物医药有限公司 |
制备环形rna的构建体、方法及其用途
|
WO2023081735A1
(en)
|
2021-11-03 |
2023-05-11 |
Celgene Corporation |
Chimeric antigen receptors specific for b-cell maturation antigen for use in treating myeloma
|
TW202334080A
(zh)
|
2021-11-08 |
2023-09-01 |
美商歐納醫療公司 |
用於遞送環狀聚核苷酸之脂質奈米粒子組合物
|
WO2023081900A1
(en)
|
2021-11-08 |
2023-05-11 |
Juno Therapeutics, Inc. |
Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
|
WO2023164440A1
(en)
|
2022-02-22 |
2023-08-31 |
Juno Therapeutics, Inc. |
Proteinase 3 (pr3) chimeric autoantibody receptor t cells and related methods and uses
|
WO2023220655A1
(en)
|
2022-05-11 |
2023-11-16 |
Celgene Corporation |
Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
|
WO2023230548A1
(en)
|
2022-05-25 |
2023-11-30 |
Celgene Corporation |
Method for predicting response to a t cell therapy
|
WO2023231959A2
(en)
|
2022-05-30 |
2023-12-07 |
Shanghai Circode Biomed Co., Ltd |
Synthetic circular rna compositions and methods of use thereof
|
WO2023250400A1
(en)
|
2022-06-22 |
2023-12-28 |
Juno Therapeutics, Inc. |
Treatment methods for second line therapy of cd19-targeted car t cells
|
WO2024006960A1
(en)
|
2022-06-29 |
2024-01-04 |
Juno Therapeutics, Inc. |
Lipid nanoparticles for delivery of nucleic acids
|
WO2024031091A2
(en)
|
2022-08-05 |
2024-02-08 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for gprc5d and bcma
|